Alexander E Berezin (Alexander Berezin)

ResearcherID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 46

Top Venues

Biomedicines

Journal of cardiovascular development and disease

Journal of clinical medicine

Diagnostics (Basel, Switzerland)

Zaporozhye State Medical University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Zaporozhye State Medical University

Ukraine

Professor :: Internal Medicine

Publications

Alexander E Berezin, Tetiana A Berezina, Uta C Hoppe, Michael Lichtenauer, Alexander A Berezin
Methods to predict heart failure in diabetes patients. Expert review of endocrinology & metabolism 19 (3) (2024)
Alexander E Berezin, Tetiana A Berezina
Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases. The Journal of international medical research 52 (2) (2024)
Alexander E Berezin
Natural bioactive ingredients as plausible anti-atherosclerotic agent: evidence and hope from calycosin. Acta cardiologica (2024)
Alexander E Berezin
Natural bioactive ingredients as plausible anti-atherosclerotic agent: evidence and hope from calycosin. Acta cardiologica 79 (5) (2024)
Alexander E Berezin
Potential harm of midodrine in renal failure patients with concomitant heart failure with reduced ejection fraction. Acta cardiologica (2024)
Tetiana A Berezina, Oleksandr O Berezin, Uta C Hoppe, Michael Lichtenauer, Alexander E Berezin
Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction. Biomedicines 12 (8) (2024)
Alexander E Berezin
Potential harm of midodrine in renal failure patients with concomitant heart failure with reduced ejection fraction. Acta cardiologica 79 (5) (2024)
Tetiana A Berezina, Oleksandr O Berezin, Uta C Hoppe, Michael Lichtenauer, Alexander E Berezin
Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction. Biomedicines 12 (8) (2024)
Tetiana A Berezina, Oleksandr O Berezin, Uta C Hoppe, Michael Lichtenauer, Alexander E Berezin
Adropin Predicts Asymptomatic Heart Failure in Patients with Type 2 Diabetes Mellitus Independent of the Levels of Natriuretic Peptides. Diagnostics (Basel, Switzerland) 14 (16) (2024)
Alexander E Berezin
Variable effect of exercise training program on cardiovascular outcomes in high genetic risk individuals with diabetes. European journal of preventive cardiology (2024)
Alexander E Berezin, Tetiana A Berezina, Uta C Hoppe, Michael Lichtenauer, Alexander A Berezin
Methods to predict heart failure in diabetes patients. Expert review of endocrinology & metabolism (2024)
Alexander E Berezin, Tetiana A Berezina, Uta C Hoppe, Michael Lichtenauer, Alexander A Berezin
Methods to predict heart failure in diabetes patients. Expert review of endocrinology & metabolism 19 (3) (2024)
Alexander E Berezin
Variable effect of exercise training programme on cardiovascular outcomes in high-genetic-risk individuals with diabetes. European journal of preventive cardiology 31 (10) (2024)
Alexander A Berezin, Anica Babic Obradovic, Ivan M Fushtey, Tetiana A Berezina, Michael Lichtenauer, Alexander E Berezin
Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of cardiovascular development and disease 10 (4) (2023)
Tetiana A Berezina, Ivan M Fushtey, Alexander A Berezin, Sergii V Pavlov, Alexander E Berezin
Predictors of Kidney Function Outcomes and Their Relation to SGLT2 Inhibitor Dapagliflozin in Patients with Type 2 Diabetes Mellitus Who Had Chronic Heart Failure. Advances in therapy (2023)
Alexander A Berezin, Anica Babic Obradovic, Ivan M Fushtey, Tetiana A Berezina, Michael Lichtenauer, Alexander E Berezin
Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of cardiovascular development and disease 10 (4) (2023)
Tetiana A Berezina, Zeljko Obradovic, Elke Boxhammer, Alexander A Berezin, Michael Lichtenauer, Alexander E Berezin
Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of clinical medicine 12 (6) (2023)
Alexander A Berezin, Anica Babic Obradovic, Ivan M Fushtey, Tetiana A Berezina, Michael Lichtenauer, Alexander E Berezin
Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of cardiovascular development and disease 10 (4) (2023)
Tetiana A Berezina, Zeljko Obradovic, Elke Boxhammer, Alexander A Berezin, Michael Lichtenauer, Alexander E Berezin
Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of clinical medicine 12 (6) (2023)
Alexander A Berezin, Zeljko Obradovic, Ivan M Fushtey, Tetiana A Berezina, Evgen V Novikov, Lukas Schmidbauer, Michael Lichtenauer, Alexander E Berezin
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines 11 (2) (2023)
Ozan Demirel, Alexander E Berezin, Moritz Mirna, Elke Boxhammer, Sarah X Gharibeh, Uta C Hoppe, Michael Lichtenauer
Biomarkers of Atrial Fibrillation Recurrence in Patients with Paroxysmal or Persistent Atrial Fibrillation Following External Direct Current Electrical Cardioversion. Biomedicines 11 (5) (2023)
Alexander A Berezin, Zeljko Obradovic, Ivan M Fushtey, Tetiana A Berezina, Evgen V Novikov, Lukas Schmidbauer, Michael Lichtenauer, Alexander E Berezin
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines 11 (2) (2023)
Alexander A Berezin, Zeljko Obradovic, Ivan M Fushtey, Tetiana A Berezina, Evgen V Novikov, Lukas Schmidbauer, Michael Lichtenauer, Alexander E Berezin
The Impact of SGLT2 Inhibitor Dapagliflozin on Adropin Serum Levels in Men and Women with Type 2 Diabetes Mellitus and Chronic Heart Failure. Biomedicines 11 (2) (2023)
Tetiana A Berezina, Alexander E Berezin
Cell-free DNA as a plausible biomarker of chronic kidney disease. Epigenomics (2023)
Kristen Kopp, Lukas Motloch, Alexander E Berezin, Victoria Maringgele, Halyna Ostapenko, Moritz Mirna, Lukas Schmutzler, Anna Dieplinger, Uta C Hoppe, Michael Lichtenauer
Missed Opportunities in Implementation and Optimization of Lipid-Lowering Therapies in Very-High-Risk Patients Presenting with ST-Segment Elevation Myocardial Infarction. Journal of clinical medicine 12 (17) (2023)
Tetiana A Berezina, Zeljko Obradovic, Elke Boxhammer, Alexander A Berezin, Michael Lichtenauer, Alexander E Berezin
Adropin Predicts Chronic Kidney Disease in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of clinical medicine 12 (6) (2023)
Alexander A Berezin, Anica Babic Obradovic, Ivan M Fushtey, Tetiana A Berezina, Michael Lichtenauer, Alexander E Berezin
Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure. Journal of cardiovascular development and disease 10 (4) (2023)
Alexander A Berezin, Zeljko Obradovic, Evgen V Novikov, Elke Boxhammer, Michael Lichtenauer, Alexander E Berezin
Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure. Diagnostics (Basel, Switzerland) 12 (12) (2022)
Alexander A Berezin, Zeljko Obradovic, Evgen V Novikov, Elke Boxhammer, Michael Lichtenauer, Alexander E Berezin
Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure. Diagnostics (Basel, Switzerland) 12 (12) (2022)
Alexander A Berezin, Ivan M Fushtey, Alexander E Berezin
Discriminative Utility of Apelin-to-NT-Pro-Brain Natriuretic Peptide Ratio for Heart Failure with Preserved Ejection Fraction among Type 2 Diabetes Mellitus Patients. Journal of cardiovascular development and disease 9 (1) (2022)
Alexander A Berezin, Michael Lichtenauer, Elke Boxhammer, Eric Stöhr, Alexander E Berezin
Discriminative Value of Serum Irisin in Prediction of Heart Failure with Different Phenotypes among Patients with Type 2 Diabetes Mellitus. Cells 11 (18) (2022)
Alexander A Berezin, Ivan M Fushtey, Sergii V Pavlov, Alexander E Berezin
Predictive value of serum irisin for chronic heart failure in patients with type 2 diabetes mellitus. Molecular biomedicine 3 (1) (2022)
Alexander E Berezin, Alexander A Berezin
Point-of-care heart failure platform: where are we now and where are we going to? Expert review of cardiovascular therapy 20 (6) (2022)
Alexander A Berezin, Zeljko Obradovic, Evgen V Novikov, Elke Boxhammer, Michael Lichtenauer, Alexander E Berezin
Interplay between Myokine Profile and Glycemic Control in Type 2 Diabetes Mellitus Patients with Heart Failure. Diagnostics (Basel, Switzerland) 12 (12) (2022)
Alexander A Berezin, Ivan M Fushtey, Alexander E Berezin
The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure. Biomedicines 10 (7) (2022)
Alexander E Berezin, Alexander A Berezin
Biomarkers in Heart Failure: From Research to Clinical Practice. Annals of laboratory medicine 43 (3) (2022)
Elke Boxhammer, Alexander E Berezin, Vera Paar, Nina Bacher, Albert Topf, Sergii Pavlov, Uta C Hoppe, Michael Lichtenauer
Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement. Journal of personalized medicine 12 (4) (2022)
Alexander E Berezin, Alexander A Berezin
Biomarkers in Heart Failure: From Research to Clinical Practice. Annals of laboratory medicine 43 (3) (2022)
Alexander E Berezin, Alexander A Berezin
Extracellular Vesicles and Thrombogenicity in Atrial Fibrillation. International journal of molecular sciences 23 (3) (2022)
Alexander E Berezin, Alexander A Berezin
Shift of conventional paradigm of heart failure treatment: from angiotensin receptor neprilysin inhibitor to sodium-glucose co-transporter 2 inhibitors? Future cardiology 17 (3) (2021)
Alexander E Berezin, Alexander A Berezin, Michael Lichtenauer
Myokines and Heart Failure: Challenging Role in Adverse Cardiac Remodeling, Myopathy, and Clinical Outcomes. Disease markers 2021 (2021)
Alexander E Berezin, Alexander A Berezin
Adverse Cardiac Remodelling after Acute Myocardial Infarction: Old and New Biomarkers. Disease markers 2020 (2020)
Olga V Petyunina, Mykola P Kopytsya, Alexander E Berezin, Olga V Skrynnyk
Subclinical emotional distress predicts 6-month clinical outcomes after ST-segment elevation myocardial infarction. Future cardiology 16 (5) (2020)
Alexander E Berezin, Alexander A Berezin
Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review. Diabetes therapy : research, treatment and education of diabetes and related disorders 11 (6) (2020)
Alexander E Berezin, Alexander A Kremzer, Yulia V Martovitskaya, Tatyana A Berezina, Tatyana A Samura
The utility of biomarker risk prediction score in patients with chronic heart failure. Clinical hypertension 22 (2016)
Alexander E Berezin
Biomarkers for cardiovascular risk in patients with diabetes. Heart (British Cardiac Society) 102 (24) (2016)

Alexander E Berezin (Alexander Berezin)

Publication Activity (10 Years)

Top Topics

Top Venues